Shernan G. Holtan

Roswell Park Comprehensive Cancer Center — United States

Medicine · Health Sciences

41h-index6.8kcitations467works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(180), Acute Myeloid Leukemia Research(58), Acute Lymphoblastic Leukemia research(47), Gut microbiota and health(42), Clostridium difficile and Clostridium perfringens research(42)

Publications466 total

Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study
2026Open Access
In the Post-Transplant Cyclophosphamide (PTCy) Era, Overall Survival (OS) By Donor Differs By Recipient and Donor Age and Race/Ethnicity
Transplantation and Cellular Therapy·2026
Induction Therapy Accelerates Immune Aging in Multiple Myeloma: Implications for Cellular Therapy Readiness
Transplantation and Cellular Therapy·2026
Improving Data Fidelity for CIBMTR Integration: The Impact of Unstructured M-Protein Reporting in Multiple Myeloma.
Transplantation and Cellular Therapy·2026
Serum Amphiregulin Differentiates Acute GI GVHD from Infectious Colitis
Transplantation and Cellular Therapy·2026
Pretreatment physical function as a risk factor for movement and neurocognitive treatment-emergent events (MNTs) in multiple myeloma (MM) patients treated with cilta-cel
Journal of the Neurological Sciences·2026
Frailty is associated with low physical activity and poor sleep quality in patients undergoing myeloablative allogeneic hematopoietic cell transplantation: a Fitbit® pilot study
Frontiers in Medical Technology·2025Open Access
Supplementary Table S1 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
2025Open Access
Supplementary Figure S2 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
2025Open Access
Supplementary Figure S3 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
2025Open Access
Supplementary Figure S5 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
2025Open Access
Supplementary Figure S6 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
2025Open Access
Supplementary Figure S4 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
2025Open Access
Supplementary Figure S1 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
2025Open Access
Analysis of epidemiologic factors and treatment effects on immunophenotypes in hematologic malignancy patients
Leukemia & lymphoma/Leukemia and lymphoma·2025
Pre-HCT creatinine defines sex-specific risk for severe TMA after allogeneic transplantation: A report from the MIDAS consortium.
Blood·2025Open Access
Accelerated immune aging after induction therapy in multiple myeloma revealed by donor-referenced immune age modeling
Blood·2025
Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution.  Results from the BMT CTN 1801 study.
Blood·2025Open Access
Overall survival after post-transplant cyclophosphamide (PTCy) peripheral blood hematopoietic cell transplantation (HCT) differs by race, ethnicity, and donor
Blood·2025
Race agnostic models maintain accuracy in predicting m-protein levels in multiple myeloma
Blood·2025Open Access
page 1 of 24Next →

Frequent Co-authors

Daniel J. Weisdorf(20), Todd E. DeFor(10), Bruce R. Blazar(10), Margaret L. MacMillan(10), Svetomir N. Markovic(10), Mukta Arora(9), Joseph Pidala(8), Armin Rashidi(8), Claudio G. Brunstein(6), Javier Bolaños‐Meade(6), Yvonne A. Efebera(6), John E. Levine(6), Tauseef Ur Rehman(6), Alexander Khoruts(6), Christopher Staley(6), Aleksandr Lazaryan(5), Amin M. Alousi(5), Douglas J. Creedon(5), James L.M. Ferrara(5), Kirk R. Schultz(5)